Bharat Serums gets CDSCO panel nod to Recombinant Anti Rho-D Immunoglobulin Injection
Advertisement
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted permission to Bharat Serums and Vaccine Limited to manufacture the additional strength of 150 mcg of Recombinant Anti Rho-D Immunoglobulin Injection.
Anti-Rho (D) immunoglobulin is a human, IGg monoclonal antibody. It is developed by Bharat Serums and Vaccines for the prevention of haemolytic disease of newborn. The product is a sterile liquid injection derived from stable heterohybridoma cell line HG-92 and purified using protein affinity chromatography.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.